Flumequine

Research use only, not for human use.

Flumequine is a synthetic chemotherapeutic antibiotic of the fluoroquinolone drug class used to treat bacterial infections.

Flumequine is a synthetic chemotherapeutic antibiotic of the fluoroquinolone drug class used to treat bacterial infections.(In Vitro):Flumequine (R-802) is a topoisomerase II inhibitor, with an IC50 of 3.92 μg/mL, and less potently inhibits Gyrase, with an IC50 of 1764 μg/mL. Flumequine (0-625 μg/mL) increases migration of nuclear DNA from CHL cells. Flumequine (R-802) inhibits Spanish field isolates of B. hyodysenteriae with MIC50 and MIC90 of 50 and 100 μg/mL, and MBC50 and MBC90 of 50, 200 μg/mL, respectively. Flumequine (R-802) suppresses A. salmonicida isolates with MIC ranging from 0.06 to 32 μg/mL.(In Vivo):Flumequine (R-802) (0-500 mg/kg, p.o.) causes dose-related DNA damage in the stomach, colon, and urinary bladder of mice, 1 and 3 h but not 24 h after its administration.

Flumequine (R-802) is a topoisomerase II inhibitor, with an IC50 of 3.92 μg/mL, and less potently inhibits Gyrase, with an IC50 of 1764 μg/mL. Flumequine (0-625 μg/mL) increases migration of nuclear DNA from CHL cells. Flumequine (R-802) inhibits Spanish field isolates of B. hyodysenteriae with MIC50 and MIC90 of 50 and 100 μg/mL, and MBC50 and MBC90 of 50, 200 μg/mL, respectively. Flumequine (R-802) suppresses A. salmonicida isolates with MIC ranging from 0.06 to 32 μg/mL.

Flumequine (R-802) (0-500 mg/kg, p.o.) causes dose-related DNA damage in the stomach, colon, and urinary bladder of mice, 1 and 3 h but not 24 h after its administration.

(±)-Flumequine

Cell Cycle/DNA Damage

Topoisomerase

Topo II

Infection

——

42835-25-6

261.25

C14H12FNO3

>98% (HPLC)

DMSO: 3 mg/mL (11.48 mM)

O=C(C(C1=O)=CN2C(C)CCC3=C2C1=CC(F)=C3)O

7-Fluoro-12-methyl-4-oxo-1-azatricyclo[7.3.1.05,13]trideca-2,5,7,9(13)-tetraene-3-carboxylic acid

(-20℃)

With Ice Pack

≥ 2 years